Sangamo Therapeutics presented primate data for ST-506, its AAV-based, one-time therapy designed to suppress PRNP expression for prion disease. The candidate uses a BBB-penetrant zinc finger transcriptional repressor delivered intravenously, aiming to reduce the production of the human prion protein implicated in disease pathology. The update reinforces Sangamo’s approach to treating neurodegeneration with gene regulation rather than gene addition, and it also provides a functional readout pathway for moving toward clinical expansion. In prion disease, where early intervention may be critical, demonstrating brain-relevant target suppression supports continued development. Further details on dosing, duration of effect, and translational biomarkers were central to the presentation, reflecting the field’s focus on durable mechanism engagement for AAV reprogramming strategies.